OLEMA PHARMACEUTICALS, INC. Operating Expenses
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Operating Expenses of $67.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $67.18M, a 40.35% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $57.99M, a 66.28% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $50.08M, a 36.22% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $45.88M, a 21.95% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $178.70M, a 25.62% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $142.26M, a 35.53% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $104.96M, a 1.89% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $106.99M, a 49.65% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.18M 10-Q · filed 2026-08-10 | $125.17M 10-Q · filed 2026-08-10 | $175.25M derived: sum of 3 quarters · filed 2026-08-10 | $221.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $57.99M 10-Q · filed 2026-05-12 | $108.07M derived: sum of 2 quarters · filed 2026-05-12 | $153.95M derived: sum of 3 quarters · filed 2026-05-12 | $201.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $50.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $95.96M derived: sum of 2 quarters · filed 2026-03-16 | $143.82M derived: sum of 3 quarters · filed 2026-08-10 | $178.70M 10-K · filed 2026-03-16 |
| 2025-09-30 | $45.88M 10-Q · filed 2025-11-10 | $93.74M derived: sum of 2 quarters · filed 2026-08-10 | $128.61M 10-Q · filed 2025-11-10 | $165.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $47.86M 10-Q · filed 2026-08-10 | $82.74M 10-Q · filed 2026-08-10 | $119.50M derived: sum of 3 quarters · filed 2026-08-10 | $157.13M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $34.87M 10-Q · filed 2026-05-12 | $71.64M derived: sum of 2 quarters · filed 2026-05-12 | $109.26M derived: sum of 3 quarters · filed 2026-05-12 | $142.79M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $36.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $74.39M derived: sum of 2 quarters · filed 2026-03-16 | $107.92M derived: sum of 3 quarters · filed 2026-03-16 | $142.26M 10-K · filed 2026-03-16 |
| 2024-09-30 | $37.62M 10-Q · filed 2025-11-10 | $71.15M derived: sum of 2 quarters · filed 2025-11-10 | $105.49M 10-Q · filed 2025-11-10 | $135.91M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $33.53M 10-Q · filed 2025-08-11 | $67.87M 10-Q · filed 2025-08-11 | $98.28M derived: sum of 3 quarters · filed 2025-08-11 | $121.63M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $34.34M 10-Q · filed 2025-05-13 | $64.75M derived: sum of 2 quarters · filed 2025-05-13 | $88.10M derived: sum of 3 quarters · filed 2025-05-13 | $109.70M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $30.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $53.76M derived: sum of 2 quarters · filed 2025-03-18 | $75.36M derived: sum of 3 quarters · filed 2025-03-18 | $104.96M 10-K · filed 2025-03-18 |
| 2023-09-30 | $23.34M 10-Q · filed 2024-11-12 | $44.94M derived: sum of 2 quarters · filed 2024-11-12 | $74.55M 10-Q · filed 2024-11-12 | $101.76M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $21.60M 10-Q · filed 2024-08-06 | $51.20M 10-Q · filed 2024-08-06 | $78.42M derived: sum of 3 quarters · filed 2024-08-06 | $101.64M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $29.60M 10-Q · filed 2024-05-08 | $56.82M derived: sum of 2 quarters · filed 2024-05-08 | $80.04M derived: sum of 3 quarters · filed 2024-05-08 | $113.34M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $27.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $50.44M derived: sum of 2 quarters · filed 2024-03-11 | $83.73M derived: sum of 3 quarters · filed 2024-03-11 | $106.99M 10-K · filed 2024-03-11 |
| 2022-09-30 | $23.22M 10-Q · filed 2023-11-07 | $56.52M derived: sum of 2 quarters · filed 2023-11-07 | $79.77M 10-Q · filed 2023-11-07 | $101.53M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $33.29M 10-Q · filed 2023-08-08 | $56.55M 10-Q · filed 2023-08-08 | $78.30M derived: sum of 3 quarters · filed 2023-08-08 | $96.07M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $23.25M 10-Q · filed 2023-05-09 | $45.01M derived: sum of 2 quarters · filed 2023-05-09 | $62.77M derived: sum of 3 quarters · filed 2023-05-09 | $79.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $21.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $39.52M derived: sum of 2 quarters · filed 2023-03-09 | $56.04M derived: sum of 3 quarters · filed 2023-03-09 | $71.49M 10-K · filed 2023-03-09 |
| 2021-09-30 | $17.76M 10-Q · filed 2022-11-08 | $34.28M derived: sum of 2 quarters · filed 2022-11-08 | $49.73M 10-Q · filed 2022-11-08 | $59.87M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $16.52M 10-Q · filed 2022-08-09 | $31.97M 10-Q · filed 2022-08-09 | $42.10M derived: sum of 3 quarters · filed 2022-08-09 | $49.97M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $15.45M 10-Q · filed 2022-05-09 | $25.58M derived: sum of 2 quarters · filed 2022-05-09 | $33.45M derived: sum of 3 quarters · filed 2022-05-09 | $35.94M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $18.00M derived: sum of 2 quarters · filed 2022-02-28 | $20.48M derived: sum of 3 quarters · filed 2022-02-28 | $21.53M 10-K · filed 2022-02-28 |
| 2020-09-30 | $7.87M 10-Q · filed 2021-11-10 | $10.35M derived: sum of 2 quarters · filed 2021-11-10 | $11.40M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $2.49M 10-Q · filed 2021-08-10 | $3.53M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $1.04M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $4.32M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |